Welcome to industryreportstore.com

Browse the latest reports in the Company Capsules industry below

77 Item(s)

Page 1 of 8

  1. THERAPEUTIC CLASS OVERVIEW : PSORIASIS – PLAQUE PSORIASIS & PSORIATIC ARTHRITIS : NOVEL ORAL DRUGS AND BIOLOGICS TO CHANGE FUTURE TREATMENT PARADIGM more info

    Plaque Psoriasis, Psoriatic Arthritis, Cimzia, certolizumab pegol, Stelara, ustekinumab, Xeljanz, tofacitinib, Alzumab, itolizumab, Remisima, biosimilar, Etacept, etanercept, OTEZLA, apremilast, Humira, adalimumab, LY3009104, ASP015K , M518101, Brodalumab, AMG 827, Secukinumab, AIN457, Ixekizumab, LY2439821, Sotrastaurin, AEB071, IL-12 and IL-23, Interleukin-17 (IL-17), JAK-STATs, INCB39110, PDE4, topical, CT327, DRM02, AN2728, DLX105, pathophysiology, guidelines, GRAPPA, AAD
    By: MP Advisors
    , Published: Feb-2014
    , Product code: 4469
    PAGES: 55 TABLES: 19 FIGURES & CHARTS: 26
    $2,500.00
  2. THERAPEUTIC CLASS OVERVIEW: TREATING REFRACTORY HEMATOLOGICAL MALIGNANCIES more info

    Relapsed or Refractory, Multiple Myeloma, immunomodulatory, Proteasome inhibitor, Kyprolis, carfilzomib, Revlimid, Onyx, Amgen, Celgene, MorphoSys, Velcade, elotuzumab, ixazomib, Daratumumab, Panobinostat, SNS01-T, Rocilinostat, Afuresertib, Siltuximab, MOR202, Myelodysplastic syndrome, azacitidine, Vidaza, decitabine, Dacogen, Estybon, rigosertib, Acute Myelogenous Leukemia, consolidation therapy, ADI-PEG 20, Vosaroxin, Quizartinib, Volasertib
    By: MP Advisors
    , Published: Feb-2014
    , Product code: 4468
    PAGES: 43 TABLES: 11 FIGURES & CHARTS: 11
    $2,500.00
  3. THERAPEUTIC CLASS OVERVIEW : EMERGENCE OF BIOGENERICS ERA IN JAPAN - IT'S TIME TO WELCOME ANTIBODY BIOSIMILARS OF FOREIGN ORIGINS SOON more info

    Japan biosimilar, Remicade, inifximab, Celtrion, Daiichi Sankyo, Kyowa Hakko Kirin, Sawai, Towa, Aska Pharma, JCR Mochida, Meiji Seika PharmaFujifilm Pharma, KisseiFuji Pharma, Nipro , Nichi Iko, Nippon Kayaku, UMN Pharma, Toyobo, Yoshindo Taiyo Toyobo, Pfizer, Amgen, Celtrion, Omnitrope, EPO, Neupogen, pegfilgrastim.
    By: MP Advisors
    , Published: Feb-2014
    , Product code: 4467
    PAGES: 31 TABLES: 49 FIGURES & CHARTS: 1
    $2,500.00
  4. THERAPEUTIC CLASS OVERVIEW: NEWER ORAL ANTI ANDROGENS – EXPANDING ROLE IN THE TREATMENT PARADIGM OF PROSTATE CANCER more info

    Androgen synthesis inhibitors, Androgen receptor, Xtandi, Zytiga, Astellas, JNJ, Medivation, Orion, Aragon, TAK-700, Takeda, ODM-201, EPI-001, Essa Pharma, TOK-001, OGX-011
    By: MP Advisors
    , Published: Feb-2014
    , Product code: 4466
    PAGES: 44 TABLES: 59 FIGURES & CHARTS: 33
    $2,500.00
  5. Global Pharmaceutical and Biotechnology Outlook 2014 :Rising Stars more info

    Ablynx, Ambit Bioscience, Basilea, Cempra, Endocyte, Enanata, Galapagos, Incyte, ISIS Pharma, MorphoSys, Onconova, Pharmacyclics, SymBio, ABLX, AMBI, BSLN, CEMP, ECYT, ENTA, GLPG, MOR, ONTX, PCYC, 4582 JP
    By: MP Advisors
    , Published: Jan-2014
    , Product code: 3464
    PAGES: 113 TABLES: 37 FIGURES & CHARTS: 52
    $2,500.00
  6. Global Pharmaceutical and Biotechnology Outlook 2014 - India Pharma  more info

    Biocon, Cipla, Dr. Reddys, Cadila Healthcre, Glenmark, Lupin, Natco,Panacea Biotech, Shasun Parma, Shilpa Medicare, Sun Pharma, DRRD, SUNP, CIPLa,BIOC,SHLP,CDH,PANC,NATCO
    By: MP Advisors
    , Published: Jan-2014
    , Product code: 3465
    PAGES: 66 TABLES: 26 FIGURES & CHARTS: 7
    $2,500.00
  7. Global Pharmaceutical and Biotechnology Outlook 2014 - Japan Pharma more info

    NHI price cut, Japan generic opportunity, Prograf, Xtandi, Isavuconazole, Myrbetriq, Astellas, Chugai, Actemra, Perjeta, biosimilar, Kadcyla, breast cancer, prostate cancer, MPDL3280A, Daiichi Sankyo, Edoxaban, Ranbaxy, Dainnipon Sumitomo, Dainnipon, cancer stem cell inhibitor, BBI-608, Latuda, DS-3025, pipeline, Halaven, Eisai, Fycompa, Belviq, Levantine, Farletuzumab, E-5501, Eritoran, E5564, Kyorin, KRP-AB1102, KRP-108, Kipres, Uritos, Mucodyne, Kyowa hakko Kirin, Mitsubishi Tanabe, Invokana, Tenelia, Gilenya, Remicade biosimilar, Nippon Kayaku, Shionogi, Tivicay, dolutegravir, Crestor, Takeda, IBD, vedolizumab, Vortioxetine, MLN-9708, Velcade, Multiple Myeloma, TAK-700, SYR-322, EDARBI, Adcetris, Japan generics, Nippon Chemiphar, Sawai, Towa
    By: MP Advisors
    , Published: Jan-2014
    , Product code: 3463
    PAGES: 141 TABLES: 45 FIGURES & CHARTS: 0
    $2,500.00
  8. Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU more info

    AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novo Nordisk, Novartis, Pfizer, Roche, GlaxoSmithKline, Outlook 2014, Global Pharmaceutical & Biotechnology Outlook 2014
    By: MP Advisors
    , Published: Jan-2014
    , Product code: 3462
    PAGES: 113 TABLES: 38 FIGURES & CHARTS: 0
    $2,500.00
  9. Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech more info

    Acorda, Alexion, Amgen, Biogen Idec, Celgene, Gilead, Regeneron, Vertex, ACOR, ALXN, AMGN, BIIB, CELG, GILD, REGN, VRTX, Soliris, Eculizumab, Asfotase alfa, Onyx, Kyprolis, RRMM, Denosumab, Prolia, XGEVA, Enbrel, Neupogen/ Neulasta, Biosimilar, Ampyra, Multiple Sclerosis, TECFIDERA, BG-12, PLEGRIDY, Gazyva, obinutuzumab, GA-101, ELOCTATE, ALPROLIX, Hemophilia A, Hemophilia B, Factor VIIIFc, Factor IXFc, Pomalidomide, POMALYST, Carfilzomib, ABRAXANE, Sotatercept, ACE-536, CC-292, MOR202, Stribild, Complera, Idelalisib, DART, Sovaldi, Sovaldi, Interferon-free treatment, Sofosbuvir/ Ledispavir, Eylea, Aflibercept, VEGF-Trap Eye, wet-AMD, Arcalyst, ZALTRAP, Alirocumab, INCIVEK, KALYDECO, KAKALYDECO/VX-809, VX-509, VX-787, VX-767, Cystic Fibrosis, G551D mutation, del508 Mutation
    By: MP Advisors
    , Published: Jan-2014
    , Product code: 2462
    PAGES: 145 TABLES: 17 FIGURES & CHARTS: 14
    $2,500.00
  10. GALAPAGOS - Strengthening ties with AbbVie – RA and Cystic Fibrosis + Partnerships of Novel Targets Opportunity Remains more info

    MP Advisors lastest report of GALAPAGOS - Strengthening ties with AbbVie – RA and Cystic Fibrosis + Partnerships of Novel Targets Opportunity Remains
    By: MP Advisors
    , Published: Oct-2013
    , Product code: 2455
    PAGES: 3 TABLES: 0 FIGURES & CHARTS: 0
    $90.00

77 Item(s)

Page 1 of 8